Sokolov 1

Researchers are conducting a phase 3 randomized, double-masked study to compare the effects of EYP-1901 against Aflibercept in patients with diabetic macular edema DME, a condition related to diabetic retinopathy. The study aims to evaluate the treatments impact on vision improvement, with a focus on the average change in best-corrected visual acuity BCVA over one year. Participants are assigned to receive either EYP-1901 or Aflibercept, both delivered by intravitreal injection directly into the eye. The study uses a parallel group design with random allocation and masking to compare these two drug treatments. The primary measurement is taken at weeks 52 and 56, with secondary outcomes including the rate of injection burden by week 56. During the study, participants will undergo regular vision assessments using the ETDRS letter score. Researchers will monitor treatment effects and safety throughout the trial period, which extends until October 2028. The total participation time includes screening, treatment, and follow-up visits designed to evaluate vision changes and treatment needs over approximately one year.

Overactive bladder OAB is a common health issue affecting 15-20% of adults, but less than half seek medical help. This research aims to raise awareness of OAB and improve referrals to specialists who can provide appropriate diagnosis and treatment. The project is led by the Institute of Health Information and Statistics of the Czech Republic and focuses on early detection and reducing the negative impact of OAB on quality of life. The study uses an online screening tool available via a web platform and mobile app, where participants complete validated questionnaires related to OAB symptoms, personal and family history, and quality of life. Those with positive screening results are offered an examination by specialists such as gynecologists, urogynaecologists, or urologists. Specialists access participant profiles through the platform, confirm or rule out OAB, perform additional diagnostic tests if needed, and set up standard treatments. Participation requires consent to data processing under GDPR. Participants will provide data through the online tool and may attend follow-up examinations with specialists. The study tracks outcomes including the number of participants completing the screening, those agreeing to specialist visits, confirmed diagnoses, and follow-up attendance over an average period of six to nine months. Data collected will evaluate the pilot projects effectiveness and cost, with all information stored securely respecting privacy regulations.

This research aims to evaluate the safety and effectiveness of EIK1001 combined with Pembrolizumab compared to placebo plus Pembrolizumab as a first treatment in patients with advanced melanoma. The study is a multicenter, randomized, double-blind, active comparator-controlled, adaptive Phase 23 trial including dose optimization and expansion parts. Participants must have advanced melanoma eligible for standard pembrolizumab therapy. Participants are assigned randomly to one of three groups placebo with Pembrolizumab, EIK1001 at dose 1 plus Pembrolizumab, or EIK1001 at dose 2 plus Pembrolizumab. EIK1001 is a dual agonist targeting Toll-like receptor 78, and Pembrolizumab is a PD-1 inhibitor. The study includes dose optimization and expansion phases to assess the treatments as first-line therapies. During the trial, participants will undergo regular assessments including imaging by CT or MRI to measure tumor response using RECIST 1.1 criteria. Safety is monitored through reports of adverse events and laboratory tests. The primary outcomes include progression-free survival and overall survival monitored up to 5 years, with additional evaluation of response duration and adverse events. Participation involves ongoing treatment and follow-up visits throughout the study period.